GINKGO BIOWORKS HOLDINGS INCDNA
ASignal's systematic analysis rates DNA as Bearish.
Reflects the latest available analysis · analyzed Sep 26, 2026
The case on DNA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong technical momentum with RSI above 80 and MACD above signal line
- Price trading significantly above upper Bollinger Band, indicating aggressive upward move
- High short interest potential for squeeze (implied by biotech sector and high beta)
- Positive free cash flow trend relative to peers in biotech space
- Severely negative operating and net margins
- Negative return on equity and assets, indicating poor capital efficiency
- Declining revenue with YoY growth at -48.5%
- Negative EV/EBITDA and forward P/E suggest unprofitable outlook
- Lack of Reddit sentiment data limits retail interest confirmation
See the full verdict on DNA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes DNA
Most investors never get a second opinion, let alone several. ASignal runs DNA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.